HSPB1 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), J2 compound that is highly cross-linked to HSP27, sensitized HSP27 highly expressing lung cancer cells to HSP90 inhibitors, taxol, and cisplatin [248].